NECVAX NEO1
Alternative Names: NECVAX-NEO1Latest Information Update: 04 Sep 2025
At a glance
- Originator NEC Corporation; VAXIMM
- Developer NEC OncoImmunity
- Class Antineoplastics; Cancer vaccines; DNA vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Solid tumours; Triple negative breast cancer
Most Recent Events
- 04 Sep 2025 NECVAX NEO1 is still in phase I development for Solid-tumours (Adjunctive treatment) in Lithuania (PO) (NCT05354323)
- 28 Jun 2025 No recent reports of development identified for phase-I development in Solid-tumours (Adjunctive treatment) in Lithuania (PO)
- 14 Oct 2024 NEC Bio Therapeutics plans a phase I/II trial for Solid tumour (Combination therapy) in October 2024 (PO) (NCT06631079)